ES2152953T3 - Anticuerpos especificos para una proteina hemostatica, su utilizacion para aislar proteinas intactas, compuestos hemostaticos carentes de productos de segmentacion proteolitica de la proteina. - Google Patents

Anticuerpos especificos para una proteina hemostatica, su utilizacion para aislar proteinas intactas, compuestos hemostaticos carentes de productos de segmentacion proteolitica de la proteina.

Info

Publication number
ES2152953T3
ES2152953T3 ES93921129T ES93921129T ES2152953T3 ES 2152953 T3 ES2152953 T3 ES 2152953T3 ES 93921129 T ES93921129 T ES 93921129T ES 93921129 T ES93921129 T ES 93921129T ES 2152953 T3 ES2152953 T3 ES 2152953T3
Authority
ES
Spain
Prior art keywords
protein
hemostatic
specific antibodies
intact proteins
compounds lack
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93921129T
Other languages
English (en)
Inventor
Koenraad Mertens
Mourik Jan Aart Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanquin
Original Assignee
Sanquin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanquin filed Critical Sanquin
Application granted granted Critical
Publication of ES2152953T3 publication Critical patent/ES2152953T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C12N9/6481—Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

METODOS PARA LA GENERACION DE ANTICUERPOS CA2+ INDEPENDIENTES, CONTRA FACTORES DE COAGULACION SANGUINEA, EMPLEANDO ESTRATEGIA DE SELECCION DE ANTICUERPOS, BASADA EN PEQUEÑOS PEPTIDOS QUE ESTAN COMPRENDIENDO SECUENCIAS OBJETIVO PARA PROTEOLISIS LIMITADA. ESTOS ANTICUERPOS, QUE SUSTANCIALMENTE SE DISTINGUEN ENTRE ESPECIES INTACTAS Y SEGMENTADAS DE LA CITADA PROTEINA HEMOSTATICA, PROPORCIONAN MEDIOS NUEVOS PARA EL AISLAMIENTO DE PROTEINAS HEMOSTATICAS INTACTAS. DEBIDO A LA AUSENCIA DE PRODUCTOS DE SEGMENTACION, QUE USUALMENTE SE ASOCIAN CON EFECTOS SECUNDARIOS O EFICACIA REDUCIDA, ESTAS PROTEINAS INTACTAS PUEDEN SERVIR COMO AGENTES DE PERFECCIONAMIENTO EN COMPOSICIONES TERAPEUTICAS PARA EL TRATAMIENTO DE TRASTORNOS HEMOSTATICOS.
ES93921129T 1992-08-27 1993-08-26 Anticuerpos especificos para una proteina hemostatica, su utilizacion para aislar proteinas intactas, compuestos hemostaticos carentes de productos de segmentacion proteolitica de la proteina. Expired - Lifetime ES2152953T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92202615 1992-08-27

Publications (1)

Publication Number Publication Date
ES2152953T3 true ES2152953T3 (es) 2001-02-16

Family

ID=8210886

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93921129T Expired - Lifetime ES2152953T3 (es) 1992-08-27 1993-08-26 Anticuerpos especificos para una proteina hemostatica, su utilizacion para aislar proteinas intactas, compuestos hemostaticos carentes de productos de segmentacion proteolitica de la proteina.

Country Status (12)

Country Link
US (2) US5932706A (es)
EP (1) EP0658168B1 (es)
JP (1) JP3735112B2 (es)
AT (1) ATE197590T1 (es)
AU (1) AU678987B2 (es)
CA (1) CA2143125C (es)
DE (1) DE69329682T2 (es)
DK (1) DK0658168T3 (es)
ES (1) ES2152953T3 (es)
GR (1) GR3035391T3 (es)
PT (1) PT658168E (es)
WO (1) WO1994005692A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US7109170B2 (en) * 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
US6624289B1 (en) * 1999-06-16 2003-09-23 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
AU2001249389A1 (en) * 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
JP2005530683A (ja) 2001-12-21 2005-10-13 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体組成物
CN101912601B (zh) 2002-06-21 2012-08-29 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
KR20060015574A (ko) 2003-05-23 2006-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 용액 중 단백질 안정화
ES2382157T3 (es) 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
EP1656158B1 (en) 2003-08-14 2016-03-09 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
FR2863616A1 (fr) * 2003-12-12 2005-06-17 Stago Diagnostica Dosage de la proteine s libre non clivee par le facteur xa et utilisation de ce dosage pour l'evaluation du potentiel de coagulation
EP1831242B1 (en) * 2004-12-23 2012-09-26 Novo Nordisk Health Care AG Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest
JP5147692B2 (ja) * 2005-07-13 2013-02-20 ノボ ノルディスク ヘルス ケア アーゲー 治療用タンパク質生成のための宿主細胞タンパク質ノックアウト細胞
CN103025757A (zh) 2010-04-29 2013-04-03 巴克斯特国际有限公司 二价阳离子结合蛋白在阴离子交换树脂上的纯化方法
PL2748179T3 (pl) * 2011-10-14 2022-04-11 Takeda Pharmaceutical Company Limited Oczyszczanie białka metodą anionowej chromatografii jonowymiennej
WO2013053888A1 (en) 2011-10-14 2013-04-18 Baxter International Inc. Protein purification by anion exchange chromatography
TR201808584T4 (tr) 2013-03-15 2018-07-23 Baxalta GmbH Anyon değişimi kromotografisi aracılığıyla k vitaminine bağlı proteinler için saflaştırma yöntemi.
AU2018216008A1 (en) 2017-02-01 2019-08-01 Novo Nordisk A/S Procoagulant antibodies
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
WO2021226243A1 (en) 2020-05-05 2021-11-11 Vega Therapeutics, Inc. Protein s antibodies, methods of making and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252712A (en) * 1980-10-20 1993-10-12 New England Medical Center Hospitals, Inc. Purified antibodies which specifically bind human abnormal prothrombin
US5055557A (en) * 1983-03-04 1991-10-08 Scripps Clinic & Research Foundation Ultrapurification of factor IX and other vitamin K-dependent proteins
US4637932A (en) * 1984-10-15 1987-01-20 Miles Laboratories, Inc. Process for producing a concentrate enriched in coagulation factors VII and VIIa
EP0229026B1 (en) * 1986-01-06 1995-11-22 Blood Systems Inc, an Arizona not-for-profit corporation Therapeutic blood product, means and methods of preparing same
DE3740520A1 (de) * 1987-11-30 1989-06-08 Hans Dr Rer Nat Scheefers Schnelles verfahren zur gewinnung einer faktor vii - praeparation sowie ihre verwendung
FI86339C (fi) * 1988-12-09 1992-08-10 Ari Tuomi Diffusionscell foer undersoekning av salvor och liknande.
US5202253A (en) * 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
CA2006684C (en) * 1988-12-30 1996-12-17 Charles T. Esmon Monoclonal antibody against protein c
AT402153B (de) * 1989-06-26 1997-02-25 Immuno Ag Protein-s-hältige pharmazeutische präparation
JP3418621B2 (ja) * 1991-03-01 2003-06-23 アヴェンティス ベーリング エルエルシー Ｉｘ因子の調製
DE4329517C2 (de) * 1993-08-30 1996-04-04 Schuelke & Mayr Gmbh Waschende Händedesinfektions- und Händedekontaminationsmittel auf Basis naturidentischer, aromatischer Alkohole
AU674586B2 (en) * 1994-07-27 1997-01-02 Rain Bird Sprinkler Manufacturing Corporation Speed controlled rotating sprinkler

Also Published As

Publication number Publication date
US5932706A (en) 1999-08-03
JP3735112B2 (ja) 2006-01-18
WO1994005692A1 (en) 1994-03-17
GR3035391T3 (en) 2001-05-31
DE69329682T2 (de) 2001-05-17
DK0658168T3 (da) 2001-01-22
DE69329682D1 (de) 2000-12-21
EP0658168A1 (en) 1995-06-21
CA2143125C (en) 2008-09-23
AU4835993A (en) 1994-03-29
AU678987B2 (en) 1997-06-19
CA2143125A1 (en) 1994-03-17
USRE38202E1 (en) 2003-07-22
ATE197590T1 (de) 2000-12-15
PT658168E (pt) 2001-04-30
EP0658168B1 (en) 2000-11-15
JPH08500833A (ja) 1996-01-30

Similar Documents

Publication Publication Date Title
DK0658168T3 (da) Antistoffer, som er specifikke for et hæmostatisk protein, anvendelse heraf til isolering af intakt protein, hæmostatiske p
DK532284D0 (da) Fremgangsmaade til bestemmelse af antigenaktive aminosyresekvenser
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
ATE177754T1 (de) Fragmente von prion proteinen.
AU640699B2 (en) Carrier for binding antiphospholipid antibody, immunoassay using the same, and kit therefor
DE69813212D1 (de) Verfahren zur erzeugung von proteinhydrolysaten
DE69703449D1 (de) Neuroaktive peptide
EP1264890A3 (en) Plasmodium vivax blood stage antigens, antibodies, and diagnostic assays
FR2816410B1 (fr) Necessaire de detection de la proteine esm-1 et procede de detection mettant en oeuvre ledit necessaire
GR3018371T3 (en) Method for identifying or determining proteins and applications therefor.
AU612683B2 (en) Synthetic peptides, antibodies directed against them, and the use thereof
ES2072490T3 (es) Procedimiento para la pasteurizacion de la proteina tisular pp4.
MÜLLER‐ESTERL et al. Limited proteolysis of human low‐molecular‐mass kininogen by tissue kallikrein: Isolation and characterization of the heavy and the light chains
ID19063A (id) Pereaksi peptida untuk deteksi cytomegalovirus (cmv)
ATE288589T1 (de) Verfahren zur analyse von proteinen
AU3563397A (en) Methods for determining the presence of brain protein s-100
ATE219247T1 (de) Methoden zur feststellung von alzheimerscher krankheit
RU98106859A (ru) Новое антитело, соединение с активностью ренина, содержащее новое антитело, и реактив для определения проренина с использованием нового антитела
DK0607425T3 (da) Epstein-Barr-viruspeptider og antistoffer mod disse peptider
AR002004A1 (es) Proteina slam, anticuerpo o un fragmento del mismo que se fija a dicha proteina, metodo de purificacion, acido nucleico que codifica dicha proteina,vector de expresion, equipo que la contiene, metodo de deteccion, metodo de modulacion y metodo para preparar una composicion farmaceutica.
ES2113492T3 (es) Metodo de valoracion de fibrinogeno, reactivo seco para dicha valoracion, y procedimiento para su preparacion.
Srinivas et al. Translocation of plasminogen activator inhibitor-1 during serum stimulated growth of mouse embryo fibroblasts
Cierniewski et al. Surface exposure of the NH2-terminal regions of the Bβ chain of the human fibrinogen
ATE301674T1 (de) Verfahren zur trennung und bestimmung von hydrophoben proteinen durch dünnschichtchromatographie
MX9602274A (es) Procedimiento para la preservacion de antigenos sin usar inhibidores enzimaticos y su aplicacion en metodos inmunologicos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 658168

Country of ref document: ES